FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED)

Editor's Note: This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV.

The U.S. Food and Drug Administration (FDA) approved a label expansion for AbbVie Inc's (NYSE:ABBV) Mavyret (glecaprevir/pibrentasvir) to include treatment of acute hepatitis C virus (HCV) infection in patients without cirrhosis or with compensated cirrhosis.

Glecaprevir, one of the two DAAs in Mavyret, was Discovered by Enanta Pharmaceuticals, Inc (NASDAQ:ENTA) and developed and commercialized by AbbVie.

Also Read: AbbVie To Present Cancer Trial Data At Upcoming ASCO Event

With this approval, Mavyret is the first ...